Clinical trials: Transitional Cell Carcinoma, open to volunteers
Muscle Invasive Upper Tract Urothelial Carcinoma
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual…
- Trial name
- NCT05595408
- Testing
- Adjuvant chemotherapy, adjuvant immunotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- RenJi Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Urothelial Carcinoma, Breast Neoplasms
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
This prospective phase Il study is aim to evaluate the efficacy and safety of FGFR inhibitor combined with immune checkpoint inhibitors in FGFR1/2/3 variant advanced solid tumors.
- Conditions
- Urothelial Carcinoma, Breast Neoplasms, Lung Cancer, Gastric Cancer
- Trial name
- NCT06551896
- Testing
- Pemigatinib
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Urothelial Carcinoma
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
This study represents an innovative opportunity in the treatment of metastatic urothelial carcinoma
- Trial name
- AVESEC (NCT07460245)
- Testing
- Avelumab 800 mg flat-dose IV
- Where
- 19 sites in Italy
- Volunteers
- 144 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Urologic Diseases, Hematuria
A Study of Ward Admissions for Haematuria
This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus…
- Conditions
- Urologic Diseases, Hematuria, Hematuria; Benign, Bladder Cancer
- Trial name
- WASHOUT (NCT07395037)
- Testing
- Inpatient work-up and management
- Where
- United Kingdom
- Volunteers
- 1,050 people
- Sponsor
- British Urology Researchers in Surgical Training
Neoplasms, Solid Tumors
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2…
- Conditions
- Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm
- Trial name
- NCT07631871
- Testing
- Zanidatamab
- Volunteers
- 10 people
- Sponsor
- Haihua Yuan
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual…
- Conditions
- Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- INSITE (NCT06396533)
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Fox Chase Cancer Center
Urothelial Carcinoma
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.
- Trial name
- NCT06405425
- Testing
- BL-B01D1, PD-1
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Urothelial Carcinoma (UC)
Korean Prospective Upper Tract Urothelial Carcinoma Cohort
This is a single-center, prospective, non-interventional observational cohort study designed to establish a structured recurrence monitoring platform in Korean patients with high-grade non-metastatic upper tract urothelial…
- Trial name
- NCT07452432
- Testing
- Peripheral blood collection for ctDNA analysis
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Samsung Medical Center
Hematuria, Cystoscopy
Bladder EpiCheck European Haematuria Study
The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria…
- Conditions
- Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06818136
- Testing
- Bladder EpiCheck
- Where
- 5 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Nucleix Ltd.
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
This study investigates the feasibility of the Labcorp Plasma Detect, which is an assay (test) that looks for circulating tumor DNA (ctDNA) in patients who have muscle-invasive (MI) urothelial carcinoma (also known as MI bladder…
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT07726602
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- OHSU Knight Cancer Institute
Urinary Bladder Cancer
Predictive Role of Microbiome in Patients With Urothelial Carcinoma
This study aims to establish the microbiota composition as a predictive tool for the response to the intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) and 2 different chemotherapies schemes.
- Trial name
- NCT06675656
- Testing
- DNA extraction from urine, stool and biopsy. Isolation of serum and PBMC from peripheral blood.
- Volunteers
- 420 people
- Sponsor
- IRCCS San Raffaele
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Non Muscle Invasive Bladder Cancer
Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT
This is a prospective, open-label, single-center, single-arm phase II clinical study to evaluate the efficacy and safety of toripalimab combined with intravesical gemcitabine as adjuvant therapy in patients with high-risk…
- Trial name
- NCT07808216
- Testing
- Toripalimab (JS001 ), Gemcitabine (GEM)
- Volunteers
- 54 people
- Sponsor
- Tianjin First Central Hospital
Urothelial Carcinoma, Urothelial Carcinoma Recurrent
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
- Trial name
- uTRACT (NCT05874921)
- Testing
- Jelmyto (mitomycin) for pyelocalyceal solution
- Where
- 22 sites in United States
- Volunteers
- 450 people
- Sponsor
- UroGen Pharma Ltd.
Oligometastatic Disease, Ureter Cancer
Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs
This study was a prospective, open-label, phase II randomised controlled clinical study, enrolling patients with primary oligometastatic uroepithelial carcinoma, oligometastasis was defined as ≤3 organs, and the number of…
- Conditions
- Oligometastatic Disease, Ureter Cancer, Renal Pelvic Carcinoma
- Trial name
- NCT06652022
- Testing
- Systematic therapy combined with radiotherapy, Systematic drug treatment
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- Peking University First Hospital
Bladder (Urothelial, Transitional Cell) Cancer, Kidney (Renal Cell) Cancer
Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.
Bladder and kidney cancers are commonly diagnosed in older adults. Surgery remains the primary treatment modality for patients with kidney or bladder cancer.
- Trial name
- FRAGECO (NCT07073703)
- Testing
- APA, Therapeutic education workshops, DAPAP
- Where
- 2 sites in France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Ureter Cancer, Renal Pelvic Carcinoma
Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC
This is a prospective cohort study to analyse the safety and efficacy of postoperative adjuvant radiotherapy combined with immunotherapy versus surgery alone group of UTUC patients with T3-4 stages or lymph nodes metastasis(N+)…
- Conditions
- Ureter Cancer, Renal Pelvic Carcinoma, Advanced Urothelial Carcinoma
- Trial name
- NCT06598761
- Testing
- Immunotherapy+radiotherapy, surveillance alone
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital